T Abshire

Summary

Affiliation: Emory University
Country: USA

Publications

  1. ncbi request reprint Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group
    T C Abshire
    Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA
    Thromb Haemost 83:811-6. 2000
  2. ncbi request reprint Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors
    T Abshire
    Aflac Cancer Center and Blood Disorders Service, Emory University, Atlanta, GA 30322, USA
    J Thromb Haemost 2:899-909. 2004
  3. doi request reprint Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors
    T Abshire
    Aflac Cancer Center and Blood Disorders Service, Emory University, Atlanta, GA, USA
    Haemophilia 14:898-902. 2008
  4. doi request reprint Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project
    R Kulkarni
    Division of Blood Disorders, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Haemophilia 15:1281-90. 2009
  5. ncbi request reprint Leukemia and P32 radionuclide synovectomy for hemophilic arthropathy
    A L Dunn
    J Thromb Haemost 3:1541-2. 2005
  6. ncbi request reprint Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates
    C L Kempton
    Aflac Cancer Center and Blood Disorders Service, Emory University, Atlanta, GA, USA
    J Thromb Haemost 4:2576-81. 2006

Detail Information

Publications6

  1. ncbi request reprint Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group
    T C Abshire
    Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA
    Thromb Haemost 83:811-6. 2000
    ..Overall, rFVIII-FS provided excellent hemostatic control, was well-tolerated, and caused no significant adverse effects, thus demonstrating safety and efficacy for treatment of bleeds in patients with hemophilia A...
  2. ncbi request reprint Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors
    T Abshire
    Aflac Cancer Center and Blood Disorders Service, Emory University, Atlanta, GA 30322, USA
    J Thromb Haemost 2:899-909. 2004
    ..Additionally, thrombotic events have not increased despite a growing experience with higher dosing of rFVIIa...
  3. doi request reprint Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors
    T Abshire
    Aflac Cancer Center and Blood Disorders Service, Emory University, Atlanta, GA, USA
    Haemophilia 14:898-902. 2008
    ..However, use of rFVIIa for off-label indications should continue to be monitored closely via clinical trials and carefully designed registries...
  4. doi request reprint Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project
    R Kulkarni
    Division of Blood Disorders, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Haemophilia 15:1281-90. 2009
    ..This study highlights the significant rate and the sites of initial bleeding unique to very young children with haemophilia and underscores the need for research to identify optimal evidence-based recommendations for their management...
  5. ncbi request reprint Leukemia and P32 radionuclide synovectomy for hemophilic arthropathy
    A L Dunn
    J Thromb Haemost 3:1541-2. 2005
  6. ncbi request reprint Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates
    C L Kempton
    Aflac Cancer Center and Blood Disorders Service, Emory University, Atlanta, GA, USA
    J Thromb Haemost 4:2576-81. 2006
    ..Understanding the baseline rate of inhibitor development in the population of previously treated patients (PTPs) is important when evaluating the effect of exposure to new factor replacement products on inhibitor formation...